leisure time -WSS

leisure time

author：Wikipedia 2025-10-01 18:08:08 - browse：8361

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Paxlovid should be available without a positive Covid test

knowledge

WSS

Sudafed saga points to U.S. issues with evaluating older drugs

HHS leader on health, climate change and biopharma emissions

FDA seeks to regulate lab

Did you have Obamacare on your GOP debate bingo card?

Mindstrong's demise and the future of mental health care

Shingles, which affected Dianne Feinstein, is on the rise

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

At least 13 dead in Texas as scorching temps continue

Kaiser Permanente unions announce official strike date

What does generative AI mean for health care? We asked experts

After a drawn out lobbying fight, ARPA

Anesthesiologist group: stop taking Ozempic before surgery

FDA gives detailed accounting of AI

Moonlake's readout produced a cash windfall. Risks remain

Intercept Pharmaceuticals sells itself for less than $1 billion

Anesthesiologist group: stop taking Ozempic before surgery

NIH confirmation hearing shows politicization of research

leisure time

HHS leader on health, climate change and biopharma emissions

Medicaid, Medicare dual

Medicare reduced heart disease by changing how it pays doctors

Cigna to pay $172 million to settle Medicare Advantage fraud probe

STAT Summit: Biotech founders on deal

Ionis has late

hotspot

Wikipedia

knowledge

entertainment